Development

The funding will support expansion of evolution-derived molecule datasets, enabling discovery of novel bioactive compounds and improving AI model performance in drug development.

FDA approval of a denosumab (Prolia) biosimilar and dual filing acceptances by FDA and EMA for an omalizumab (Xolair) biosimilar candidate from Teva signal increasing competition in the biosimilar markets as well as expanded access for allergy and immunology patients.

Christopher Locher, PhD, CEO, Versatope Therapeutics, discusses how emerging vaccine platforms are advancing the pursuit of a universal influenza vaccine, while highlighting the scientific, regulatory, and economic barriers that continue to shape its path to reality.

The approval introduces a one-time gene therapy for LAD-I that restores immune function and addresses the underlying cause of a life-threatening pediatric disease.

Bristol Myers Squibb’s Dr. Manisha Desai, senior vice president of Product Development, notes how strategic bioprocessing alliances accelerate drug development by integrating R&D and manufacturing to scale complex biologics and ensure reliability.

FDA’s approval of a high-dose nusinersen from Biogen improves SMA treatment durability and supports evolving therapy sequencing strategies in a competitive neuromuscular market.

Webinar Date/Time: Fri, Apr 17, 2026 11:00 AM EDT Add to Calendar

Phase 3 data from AstraZeneca show IL-33 inhibition reduces COPD exacerbations across broad populations, supporting a new biologic approach beyond eosinophil-driven disease.

In a new collaboration, Tempus and Daiichi Sankyo will apply AI-driven biomarker discovery to improve ADC patient selection with the aim of advancing precision strategies in competitive oncology pipelines.

Novo Nordisk and TUL report phase 2 data showing UBT251 delivers strong glycemic and weight reductions, making it a strong contender in the GLP-1 arena.

GSK’s B7-H3-targeted ADC has shown durable responses in SCLC, supporting regulatory momentum and advancing targeted approaches for high-unmet-need lung cancers.

With the license, Sanofi gains Kali Therapeutics’ tri-specific T-cell engager pipeline candidate, KT501, which targets B cell-mediated autoimmune diseases.

The hub will integrate the company’s manufacturing and R&D in China to streamline CAR-T development while addressing scalability and accelerating regional access to advanced therapies.

With Sanofi as one of its backers, Earendil Labs is set to advance its AI-native biologics platform to scale antibody discovery, accelerate IND filings, and expand partnerships in autoimmune and oncology research.

Phase III data show retatrutide reduces HbA1c and body weight, supporting triple-agonist strategies for metabolic disease treatment.

The launch of Excalipoint Therapeutics brings to the table multi-specific T-cell engager platforms that aim to overcome tumor microenvironment barriers and expand efficacy into solid tumors and immunology indications.

Data from a Phase III trial showed durable survival benefit with PD-L1 blockade plus chemotherapy, reinforcing the use of immunotherapy in curative-intent GI cancer settings.

The current Middle East conflict is disrupting Gulf air and sea hubs, forcing bio/pharma firms to reroute cold-chain drug shipments and raising risks of oncology medicine shortages.

Regulatory acceptance of tildrakizumab's sBLA signals a potential expansion of IL-23 inhibition into joint disease, an area in which treatment gaps persist for a substantial share of psoriatic disease patients.

The companies’ new immunology-driven mAb, which targets an immune-evasion pathway in myeloproliferative neoplasms, is advancing toward first-in-human trials.

Early-phase clinical trials are becoming more complex and data-driven, requiring emerging biotechs to incorporate biomarker strategies, exposure–response analyses, and regulatory planning into Phase I study design while carefully considering CRO selection, operational continuity, and trial geography.

The company is targeting the $3 billion pancreatic cancer market with its lead proenzyme therapy candidate, PRP, which is supported by strong preclinical tumor inhibition data and for which a PK assay will be developed and validated.

Results from a head-to-head study highlight cytokine-targeting differences between UCB’s bimekizumab and risankizumab, strengthening evidence for dual IL-17 blockade in psoriatic arthritis therapy

The new clinical data show biomarker reductions and new motor milestones with salanersen, which supports once-yearly antisense therapy development in spinal muscular atrophy.

Data from the MajesTEC-9 Phase III trial shows teclistamab as monotherapy improves survival, indicating a shift in multiple myeloma treatment.